News | October 31, 2011

New Data Demonstrates Positron Emission Mammography Has Higher Sensitivity Than PET/CT

October 31, 2011 – The Breast journal published new data from a prospective study conducted at the Seoul National University College of Medicine in Korea that shows positron emission mammography (PEM) has a higher sensitivity for tumor detection compared with whole-body positron emission tomography (PET)/ computed tomography (CT) when using both visual as well as quantitative analysis. These results were particularly striking and significant for smaller-sized tumors (less than 2 cm), likely due to the improved spatial resolution offered by PEM. This demonstrates PEM's clinical utility in being able to more effectively diagnosis early stage cancer.

According to recent journal articles, the sensitivity of PET/CT is limited, especially for low-grade and small tumors. Most PET/CT scanners currently provide a spatial resolution at 5 mm or greater, thus limiting PET/CT's ability to depict small-sized tumors such as invasive lobular carcinoma or ductal carcinoma in situ. This study provides a direct comparison within the same patient population.

A total of 113 breast lesions from 101 patients with a mean tumor size of 2.2 cm, were included in the analysis. The patients underwent PEM with FDG and whole-body PET/CT before surgical resection. The images were then analyzed visually and quantitatively using the tumor-to-normal tissue uptake ratio (TNR) with a cutoff of 2.5 or greater. The tumors were classified into 4 groups based on size using pathology measurements prior to detection sensitivity analysis for PEM and PET/CT. In visual analysis, the overall sensitivity of PEM was 95 percent, which was significantly higher than the 87 percent sensitivity found for PET/CT; ( p=0.004). In addition, the TNR of PEM was significantly higher than that of PET/CT in small tumors (<1 cm; p=0.005 and <2 cm; p<0.001).

PEM is the breast application of the Naviscan high-resolution PET scanner, which both can localize as well as characterize the metabolic activity of a lesion. PEM uses parallel photon detectors in a configuration similar to mammography with breast immobilization, not compression. It is the only U.S. Food and Drug Administration (FDA)-cleared, CE Certified 3-D molecular breast imaging (MBI) device on the market. The metabolic view assists physicians in making optimal care decisions by providing an ability to distinguish between benign and malignant lesions.

For more information: www.naviscan.com

 

Related Content

Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
California Women In Favor of Extending State's Breast Density Inform Law
News | Breast Density | June 15, 2018
A recent survey of California women found that 95 percent of respondents want the state’s breast density inform law to...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
High Prevalence of Atherosclerosis Found in Lower Risk Patients
News | Magnetic Resonance Imaging (MRI) | June 08, 2018
Whole-body magnetic resonance angiography (MRA) found a surprisingly high prevalence of atherosclerosis in people...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Overlay Init